Forty percent of hormone-receptor positive breast cancer patients are unresponsive to standard hormone/endocrine therapy, but recent research has shown anti-androgen therapies are a promising alternative, according to the release.
“The objective of our project is to design a therapeutic strategy to effectively target this hyperactive modified AR and prevent metastatic progression of ET-insensitive HR-positive breast cancer,” said Dr. Bawa-Khalfe.
“Working with collaborators in the UH College of Pharmacy and Lester and Sue Smith Breast Cancer Center at Baylor College of Medicine, we have identified actionable/druggable targets and corresponding molecular pathways that support accumulation of the active AR,” Dr. Bawa-Khalfe said. “We expect to generate novel therapeutics and evaluate clinically relevant compounds to inhibit these targets and in turn prevent metastatic progression of advanced ET-resistant breast cancer.”
